INTRAVITREAL SUSTAINED RELEASE STEROID IMPLANTS ARE SAFE AND EFFECTIVE IN PATIENTS WITH GLAUCOMA DRAINAGE DEVICES

Area of Science:

• Ophthalmology
• Glaucoma Research
• Drug Delivery Systems

Background:

• Glaucoma drainage devices are used to manage intraocular pressure (IOP) in complex glaucoma cases.
• Sustained-release steroid implants offer a localized treatment option for ocular inflammation and edema.

Purpose of the Study:

• To evaluate the effect of sustained-release steroid delivery devices on IOP in eyes previously treated with glaucoma drainage devices.
• To assess the safety and efficacy of intravitreal steroid implants in this patient population.

Main Methods:

• A retrospective case series included 14 eyes with pre-existing glaucoma drainage devices (Ahmed, Baerveldt) receiving steroid implants (dexamethasone or fluocinolone acetonide).
• Outcomes measured included intraocular pressure (IOP), changes in IOP, central foveal thickness, and IOP-lowering medication use.

Main Results:

• Mean IOP showed a trend towards reduction at 1 year (P = 0.032).
• Significant reduction in central foveal thickness was observed (P = 0.001).
• No increase in IOP or need for additional antihypertensive medications was noted; no endophthalmitis occurred.

Conclusions:

• Intravitreal steroid implants are safe and effective in managing postsurgical cystoid macular edema (CME) in patients with glaucoma drainage devices.
• These implants do not appear to elevate IOP or increase medication burden in this specific cohort.